For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in theJournal of Clinical Oncology. (HealthDay) -- For ...
ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC Spencer Feldman December 21st 2024 Article The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer. ...
e20010#Background:The treatment of heavily pretreated Multiple Myeloma continues to be considered as an important unmet clinical need. Bendamustine is an old bi-functional alkylating agent which has proved to be effective in relapsed, refractory and in new diagnosed Multiple Myeloma (MM). Thus, ...
Progress in the treatment of patients with hairy cell leukemia (HCL) has led to a significant change in the natural history of the disease. With current re... Farhad,Ravandi - 《Clinical Lymphoma & Myeloma》 被引量: 27发表: 2009年 A Rare Clinical Case of Secondary Central Nervous System ...
also help determine when the cancer has been reduced sufficiently that therapy can be stopped. This test may be done every 1 – 2 months. Maintrac CTC is designed to measure carcinomas, but can be used for sarcoma, glioblastoma and other cancer types (not for myeloma, lymphoma or leukemia...
This strategy can be applied for the treatment of several types of cancer, including lymphoma, leukemia, liver cancer carcinoma of prostate, intestine cancer, myeloma tumor, lymphoma, breast carcinoma, and ovarian cancer [34]. In a study conducted by Quan et al. [35], the authors designed a...
this treatment option doesn’t eliminate the side effects entirely. Patients can still experience some side effects, such as low white blood cell counts and hair loss. But, overall, it allows for a safer delivery system for the drugs needed to prolong their lives and help cull the cancer ...
Four-year data from the phase 2 PONALFIL trial, which evaluated a regimen consisting of ponatinib (Iclusig), chemotherapy, and allogeneic hematopoietic stem cell transplantation (alloHSCT), showed potential to lead to long-term survival when used as treatment for adult patients with newly ...
3) This chemoresistant model preferentially selected for cells with active OXPHOS. This potential bias may result from species differences, specific chemoregimens applied, and/or retention of a high number of AML cells after treatment. Fig. 8 Working model. In AML, HSPC-like leukemic cell ...
Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.